See more : Teac Corporation (6803.T) Income Statement Analysis – Financial Results
Complete financial analysis of Rhythm Pharmaceuticals, Inc. (RYTM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rhythm Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- La Kaffa International Co., Ltd. (2732.TWO) Income Statement Analysis – Financial Results
- FirstService Corporation (FSV.TO) Income Statement Analysis – Financial Results
- Adtiger Corporations Limited (1163.HK) Income Statement Analysis – Financial Results
- Yotta Acquisition Corporation (YOTAU) Income Statement Analysis – Financial Results
- Rama Steel Tubes Limited (RAMASTEEL.BO) Income Statement Analysis – Financial Results
Rhythm Pharmaceuticals, Inc. (RYTM)
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.43M | 23.64M | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.30M | 2.13M | 599.00K | 690.00K | 834.00K | 442.00K | 223.00K | 144.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 68.13M | 21.51M | 2.56M | -690.00K | -834.00K | -442.00K | -223.00K | -144.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 87.99% | 90.98% | 81.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 134.95M | 108.63M | 104.13M | 90.45M | 109.45M | 50.34M | 22.89M | 19.59M | 7.15M | 5.28M | 18.02M | 15.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.08M | 9.52M | 6.31M | 3.43M | 1.21M | 3.43M | 2.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 117.53M | 92.03M | 68.49M | 46.13M | 36.55M | 28.08M | 9.52M | 6.31M | 3.43M | 1.21M | 3.43M | 2.46M |
| Other Expenses | 0.00 | -790.00K | 100.00M | 0.00 | 0.00 | 0.00 | -1.86M | 0.00 | -500.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 252.48M | 200.66M | 172.61M | 136.58M | 146.00M | 78.42M | 32.41M | 25.91M | 10.57M | 6.49M | 21.45M | 18.14M |
| Cost & Expenses | 261.79M | 202.80M | 173.21M | 136.58M | 146.00M | 78.42M | 32.41M | 25.91M | 10.57M | 6.49M | 21.45M | 18.14M |
| Interest Income | 13.95M | 4.03M | 447.00K | 2.58M | 5.27M | 4.35M | 566.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.89M | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.76M | 1.40M | 1.16M | 690.00K | 834.00K | 442.00K | 223.00K | 144.00K | 500.00K | 6.49M | 20.00K | 17.00K |
| EBITDA | -168.46M | -174.52M | -68.45M | -135.89M | -145.17M | -77.98M | -32.19M | -25.76M | -10.07M | 0.00 | -21.41M | -18.12M |
| EBITDA Ratio | -217.58% | -744.22% | -5,391.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -184.36M | -179.16M | -170.06M | -136.58M | -146.00M | -78.42M | -32.41M | -25.91M | -10.57M | -6.49M | -21.45M | -18.14M |
| Operating Income Ratio | -238.10% | -757.92% | -5,391.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 243.00K | -1.96M | 100.45M | 2.58M | 5.27M | 4.35M | -1.30M | 33.00K | -500.00K | 0.00 | 17.00K | 8.00K |
| Income Before Tax | -184.11M | -181.12M | -69.61M | -134.00M | -140.73M | -74.06M | -33.71M | -25.87M | -11.07M | -6.49M | -21.43M | -18.13M |
| Income Before Tax Ratio | -237.79% | -766.22% | -2,207.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 564.00K | 1.96M | -1.61M | -3.27M | -6.11M | 4.35M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -184.68M | -183.08M | -68.01M | -130.73M | -134.62M | -74.06M | -33.71M | -25.87M | -11.07M | -6.49M | -21.43M | -18.13M |
| Net Income Ratio | -238.52% | -774.52% | -2,156.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| EPS Diluted | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| Weighted Avg Shares Out | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 16.73M | 16.73M | 10.20M | 50.27M | 50.27M |
| Weighted Avg Shares Out (Dil) | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 16.73M | 16.73M | 10.20M | 50.27M | 50.27M |
Rhythm Pharma: An Incremental Approach Works Well For Setmelanotide
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2022 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
3 Healthcare Stocks That Are Beating the Market
These Are The Ten Best And Worst Performing Small-Cap Stocks In July 2022
Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference
Why Rhythm Pharmaceuticals Stock Is Rocketing Higher Today
Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q2 2022 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports